(Pittsburgh, PA)
 — The Foundation for Mitochondrial Medicine (FMM) and the United Mitochondrial Disease Foundation (UMDF) are excited to announce an agreement to combine and advance their synergistic missions of advancing research, education and patient support for treatments of mitochondrial disease.  FMM made this decision after careful strategic consideration for opportunities to generate greater critical mass and serve a greater number of patients and families.

Atlanta-based FMM has been dedicated to supporting the development of the most promising research and treatments for the many forms of mitochondrial disease. The foundation was formed by parents of patients with mitochondrial disease and medical experts. Since its relaunch in 2010, FMM has focused on raising awareness for mitochondrial disease, fueling connections to related diseases and funding treatment-oriented research.  In addition to hosting and sponsoring a variety of awareness and informational programs to help further its mission, FMM has co-funded research projects with partners like the Alzheimer’s Drug Discovery Foundation and the Michael J. Fox Foundation for Parkinson’s Research

“This is an exciting opportunity for the community at-large to unify and become stronger together,” said Laura Stanley, Executive Director of FMM.  “Consolidation and integration is the right thing to support the patient community and to grow the collective voice for all mitochondrial disease patients.”   Stanley said that FMM is thrilled about the opportunity to join with the UMDF. “Our goal was to secure a like-minded relationship to harvest the plantings of FMM’s good work, and UMDF is the perfect organization to carry on the FMM legacy.”

Since 1996, UMDF has provided education and support to patients and families, has advocated in favor of issues that impact the entire mitochondrial disease community and has awarded more than $13 million in research towards treatments and cures.

Brian T. Harman, President and CEO of UMDF, said the organization is honored that FMM chose UMDF to carry on the FMM legacy.  “We recognize the tremendous work done over the years by FMM for the scientific and patient community,” Harman said.  “We are grateful for this opportunity because FMM’s priorities align with UMDF’s mission.”  In welcoming FMM, Harman said the combination of the organizations will clearly benefit the entire patient community because both focus on treatments and cures for mitochondrial disease.

On January 1, 2019, the daily operations at the Foundation for Mitochondrial Medicine (FMM) will transfer to the United Mitochondrial Disease Foundation (UMDF).

See our ‘Frequently Asked Questions’ page for addtional information.